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The human T  cell leukemia-lymphoma virus (HTLV) l  is a  novel retrovirus 
associated with adult T  cell leukemia (ATL) and lymphoma and shows a unique 
geographical distribution to southern Japan, the southeastern United States, the 
West Indies, and other areas (1).  Studies using HTLV-associated patient serum 
(2-4) or a monoclonal antibody (12/1-2) against a  19,000 dalton component of 
HTLV  (p19)  (5,  6),  as  well  as  nucleic acid  hybridization  studies  (7-9),  have 
demonstrated  that  HTLV  isolates  from Japanese  ATL and  cutaneous T  cell 
lymphoma from patients in the U. S. are highly related or identical. Serological 
studies demonstrated HTLV-associated patient sera immunoprecipitated HTLV 
proteins of  19,000  and  24,000  daltons from  125I-labeled HTLV  preparations 
(10), and that both p19 and p24 copurify with viral core structures, suggesting 
that they are  structural  core proteins of HTLV  (11).  Data from the complete 
nucleotide sequence of the proviral HTLV genome (12) as well as partial amino 
acid analysis of the p24 protein of HTLV (13,  14) indicate further that HTLV 
proteins p19 and p24 are encoded by the gag region of the viral genome. 
Monoclonal  antibody  12/1-2,  which  reacts  with  the  p19  core  protein  of 
HTLV, has been a useful diagnostic reagent for the detection of HTLV-infected 
T  cells (5,  6).  However,  the antigenic determinant recognized by monoclonal 
antibody  12/1-2  is also  present  on  normal  thymic epithelium and  on  other 
normal and neoplastic epithelial cells, and therefore is not strictly HTLV specific 
(15).  In addition, no anti-HTLV p24  monoclonal antibodies have been made, 
and  only limited quantities  of polyclonal  goat antiserum  to  HTLV  p24  core 
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protein are available as a probe for the detection of p24 in HTLV-infected cells. 
Moreover, use of the polyclonal goat anti-p24 in fluorescent assays has not been 
useful for HTLV cellular localization (10). Thus, in the present study, we raised 
monoclonal antibodies against HTLV p24 and used them as diagnostic reagents 
for detection of HTLV-infected cells, to study the cellular localization of p24, 
and to evaluate whether there is any shared antigenicity between p24 and normal 
human tissue, as has been found for HTLV p19 (15). We report here that four 
monoclonal antibodies (HTLV 6,  7,  8, and 9) raised against disrupted HTLV 
reacted with the p24  internal core protein of HTLV and with HTLV-infected 
T  cells,  but  did  not  react  with  a  wide  range  of normal,  neoplastic,  or  non- 
HTLV-infected  human  cells  and  tissues.  In  addition,  monoclonal  antibodies 
HTLV 6,  7,  8, and 9  identified at least two antigenic sites on HTLV p24  that 
are both recognized by antibodies in HTLV  + patient sera. Antibodies HTLV 6, 
7,  8,  and 9  also reacted with a  T  cell  line from umbilical cord blood infected 
with HTLV-IIMo, a  new type of HTLV. This virus was located from a  patient 
(MO) with a  T  cell variant of hairy cell leukemia. Finally, HTLV p24  internal 
core protein  was localized at the cell surface of HTLV-infected T  cells and is 
likely associated with areas of budding virus particles. 
Materials and Methods 
Production of Monoclonal Antibodies.  On days 0,  7,  14, and 21,  BALB/c mice were 
immunized with subcutaneous and footpad injections of 50  t~g disrupted HTLV (see 
below) in complete (day 0) and incomplete (days 7, 14, and 21) Freund's adjuvant. Before 
fusion, sera from immunized mice were screened for antibodies to HTLV by solid-phase 
radioimmunoassay (RIA) (6) and radioimmunoprecipitation (RIP) assay (16). Spleen cells 
from mice with circulating antibodies to HTLV were fused with one of the myeloma cell 
lines  P3/63/Ag8,  NS1-Ag4, or 653,  using polyethylene glycol  1000  as previously de- 
scribed (17). After 10-14 d, colony supernatants were screened for anti-HTLV antibodies 
by solid-phase RIA. Positive colonies were passaged into 24-well plates and rescreened for 
reactivity to disrupted HTLV using the RIP assay or the Western blotting technique 
described below. Positive colonies were cloned by limiting dilution until successive cionings 
gave 100% positive cultures, and then passaged as ascites tumors. 
Tissue and Cell Suspension Assays for Anti-HTLV Antibody Reactivity.  Hybridoma super- 
natants and ascitic  fluid were screened for reactivity with 4-um frozen sections from a 
wide variety of types of tissues using indirect immunofluorescence as previously described 
(18). In some experiments, antibody HTLV 6 was directly fluoresceinated (fluorescein/ 
protein ratio [F/P], 5.6) and used in direct fluorescence as described (18,  19). HUT 102, 
HUT 78, EB-3, SB, and HSB-2 cell lines were obtained and cultured as described (19). 
Cytocentrifuge preparations of cell lines, Hypaque-Ficoll-purified fresh normal peripheral 
blood leukocytes (PBL), and HTLV  ÷ patient PBL cultured in 25% T  cell growth factor 
(Enzyme Center, Boston, MA) for 5 d  were prepared, acetone fixed, and assayed for 
reactivity  with  anti-HTLV  monoclonal  antibodies  or  P3/63  control  ascites  fluid as 
previously described (10). 
Viral Preparations and Antibody Reagents.  HTLV was collected from HTLV  + HUT 102 
cell culture supernatants by continuous flow centrifugation and was purified by banding 
on sucrose density gradients as previously described (20).  The virus was disrupted in 
Triton X-100 as described (16) and used in RIP or Western blot assays or extracted once 
with a threefold volume of diethyl ether and used in the solid-phase RIA. Goat polyclonai 
antisera against purified p24 and monoclonai antibody 12/1-2  that reacts with HTLV 
p 19 core protein (5) were the generous gifts of Dr. V. Kalyanaraman and Dr. M. Robert- 
Guroff (NCI, NIH), respectively. HTLV  ÷ patient serum used in preclearing experiments 
was from patient SD with Japanese ATL (10). PALKER  ET  AL.  1119 
Solid-Phase R/A.  A solid-phase RIA (6) was used to detect hybridoma cell supernatants 
containing antibodies to HTLV proteins. An ether-extracted HTLV protein preparation 
was diluted in  15 mM NaHCO3, 35 mM Na~COs, pH 9.6 (coating buffer), and 100 ng in 
50 #1 coating buffer was added  to detachable wells  of Immulon plastic microtiter well 
strips (Dynatech Laboratories, Inc., Alexandria, VA). After overnight absorption at 4°C, 
wells were washed and incubated for 2 h at 4°C in coating buffer with 3% bovine serum 
albumin (BSA)  and 0.02%  NaN3 to block nonspecific protein binding sites.  Plates were 
stored at -20°C until used. Before assay, plate wells were washed three times with 100 #i 
of phosphate-buffered saline (PBS),  pH 7.2, containing 0.5% Tween 20, 0.1% BSA, and 
0.1% NaNs (PBS wash), and incubated for 1 h at 23 °C with 50 #1 ofhybridoma supernatant 
diluted  1:2 in PBS, 0.5% Tween 20,  1% BSA, 0.1% NaNs (PBS diluent). After washing, 
1:200 to 1:500 dilutions of rabbit anti-mouse IgG + M whole serum (Cappei Laboratories, 
Cochranville, PA) in PBS diluent were added and incubated for 30 min at 23°C.  Plate 
wells  were washed and incubated with  100,000  cpm of l~I-protein A  in  50 gi of PBS 
diluent  for  30  min  at  23°C.  Wells  were  emptied,  washed  five times  with  PBS  wash, 
separated, and counted for 1 min in a gamma counter. 
Studies of Antigenic Sites  on HTLV p24 Identified by HTLV 6,  7,  8,  and 9  and by HTLV + 
Patient Sera.  Monoclonal antibodies  HTLV 6,  7,  8,  and  9  were isolated from mouse 
ascites fluid using protein A-Sepharose (21) and were iodinated using Iodobeads (Pierce 
Chemical Co.,  Rockford, IL). A competitive inhibition assay to compare the reactivities 
of HTLV 6,  7, and  8  and  HTLV  ÷ patient sera to antigenic  sites on  HTLV p24  was 
performed as previously described (6) with some modifications. Briefly, duplicate micro- 
titer wells precoated with HTLV proteins (1-2 #g/well) as described above were incubated 
with dilutions of unlabeled HTLV 6, 7, 8, and 9 or HTLV  + patient sera in PBS diluent 
buffer for 45 min at 23°C.  Wells were washed with PBS wash buffer and then further 
incubated with  105 cpm of 125I-labeled HTLV 6, 7, 8, or 9 in PBS diluent buffer for 45 
rain at 23°C. Wells were washed as before and counted in a gamma counter. For controls, 
HTLV-coated wells were incubated with dilutions of P3X63 ascites fluid or pooled normal 
human  serum  and  then  used  in  the  assay  to  estimate  100%  binding  of radiolabeled 
antibody. To estimate 0% binding of the radiolabeled antibody, HTLV-coated wells were 
incubated with a  1:100 dilution of the appropriate unlabeled anti-p24 antibody and the 
assay was completed as described. 
Radioimmunoprecipitation  of 125I-HTLV.  HTLV preparations were iodinated  with  Io- 
dogen (Pierce Chemical Co.) in the following manner: Briefly, 10 #g of Iodogen in  100 
#l chloroform was dried to the bottom of a  12 x  75-mm test tube under a stream of dry 
nitrogen and tubes were stored at 4°C in a dessicator until used.  For labeling,  10 #g of 
HTLV protein in 10 #1 PBS, pH 7.2, were incubated in Iodogen-coated tubes for 15 rain 
at 23°C with 0.5 mCi 125I (Amersham Corp., Arlington Heights, IL). The mixture was 
passed over a  PD-10  column  (Pharmacia  Inc.,  Piscataway,  NJ)  equilibrated  with  RIP 
buffer (10 mM sodium phosphate, pH 7.5,  300 mM NaC1, 0.2%  Triton X-100, 0.01% 
Tween 80, 0.1% gelatin, 0.02% NaNs) and labeled HTLV proteins were eluted with RIP 
buffer and stored at -20°C. For screening of sera from mice immunized with HTLV, 5 
#l of test or normal control serum was added to 500 #l of RIP buffer containing 5 ×  105 
cpm of ~25I-HTLV and incubated overnight at 4°C. Immune complexes were precipitated 
by adding  100  #1 of 10%  fixed Staphylococcus  aureus  Cowan  I  strain  (SAC) (Pansorbin; 
Calbiochem-Behring Corp., La Jolla, CA) in RIP buffer and incubating for 1 h at 4°C. 
Pellets were washed three times in RIP buffer and immunoprecipitates were analyzed by 
sodium  dodecyl  sulfate-polyacrylamide gel  electrophoresis  (SDS-PAGE)  (22)  on  10% 
polyacrylamide gels. 
Predearing  of I~5I-HTLV with  anti-HTLV  Monoclonal  Antibodies  or HTLV + ATL  Patient 
Serum.  To compare the reactivity of antibodies in sera of patients with HTLV with that 
of murine monocional antibodies raised to HTLV, preclearing experiments were under- 
taken in the following manner. To compare antibody A with antibody B, 5 x  105 cpm of 
~25I-HTLV in 500 #! of RIP buffer were incubated overnight with the amount of antibody 
A that resulted in optimum precipitation of ~5I-HTLV, as determined by titration studies. 
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monoclonal antibodies or patient serum, titration curves were derived using 0.5-40 #1 of 
monoclonal antibody ascites or patient serum, 5 ×  105 cpm of 125I-HTLV in 500 #! of 
RIP buffer, and 100 ~i of 10% SAC. All antibody precipitations were done overnight at 
4°C. To immunoprecipitate HTLV p24 optimally with HTLV 7, 8, or 9, immunoprecip- 
itation was performed with SAC precoated with rabbit anti-mouse IgG +  IgM (23). The 
amount of antibody that precipitated the maximum number of counts in titration studies 
was  used  in  preclearing experiments described below.  After precipitation of immune 
complexes with SAC, the precleared 12~I-HTLV samples were again precipitated overnight 
with a half volume of antibody A and SAC, followed by an additional 1 h incubation with 
SAC alone. When preclearing with HTLV  ÷ ATL patient serum, a third preclearing with 
a half volume of antibody plus SAC was required to preclear HTLV samples.  For the 
final RIP, an optimum amount of antibody B plus SAC was added to the precleared ~25I- 
HTLV sample. For each preclearing experiment using antibodies A and B, the following 
controls were included: (a) preclearing with A and RIP with A, (b) preclearing with A and 
RIP  with  normal  antibody  control  (normal  human  serum,  normal  mouse  serum,  or 
P3X63/Ag8 ascites) for A, (c) preclearing with A and RIP with B, (d) preclearing with A 
and RIP with normal antibody control for B (normal human serum, normal mouse serum, 
or P3X63/Ag8 ascites),  (e) preclearing with normal control for A and RIP with A, (jr) 
preclearing with normal control for A and RIP with normal antibody control for A, (g) 
preclearing with  normal antibody control for B and  RIP with  B, (h) preclearing with 
normal antibody control for B and RIP with normal antibody control for B, and (i) RIP 
with A  and  B and normal antibody controls without preclearing. Immunoprecipitates 
were electrophoresed on 10% polyacrylamide gels and autoradiographed for 2 d at -70°C 
using Kodak X-omat film and Dupont Lightning Plus intensifying screens. 
Western Blotting of HTLV.  Western blotting of HTLV was performed according to the 
technique of Towbin et al. (24). Following SDS-PAGE of 0.5-2.5 t~g of disrupted HTLV 
protein under reducing or nonreducing conditions, HTLV proteins were electrophoreti- 
cally transferred to nitrocellulose sheets (Schleicher & Schuell, Inc., Keene, NH) using an 
electrode buffer of 25 mM Tris,  192 mM glycine, 20% (vol/vol) methanol, pH 8.3, for 
45 min at 0.7-0.9 A. Following the transfer, the nitrocellulose sheet was treated with 3% 
BSA in Tris-buffered saline (TBS) (0.9% NaC1, 10 mM Tris, pH 7.4) for 2 h at 23°C to 
block additional nonspecific protein binding sites.  Individual lanes were then incubated 
with monoclonal antibody supernatants  diluted  1:5  for 2  h  at  23°C.  Strips were then 
washed in TBS five times for 5 min each in 16 ×  150 test tubes, incubated for 30 min at 
23°C in 2 ml of 3% BSA-TBS containing 10  ~ cpm/ml of 125I-labeled sheep anti-mouse 
IgG + M F(ab')2 fragment (Amersham Corp.), washed five to eight times in TBS, blotted 
dry, and autoradiographed for 2  h  with an  intensifying screen.  ~4C-labeled molecular 
weight markers that were transferred from the gel to the nitrocellulose served as internal 
molecular weight standards. 
Electron Microscopy.  HUT  102  cells  were fixed by the addition of a  volume of 2% 
glutaraldehyde in  0.1  M  phosphate buffer with  1.8%  sucrose equal to the volume of 
media  in  the  flask.  After  30  rain,  cells  were  pelleted  at  low  speed,  and  fresh  1% 
glutaraldehyde in phosphate/sucrose buffer was added for an additional 60 min. Postfix- 
ation was in  1% osmium tetroxide in phosphate buffer for 30 min followed by staining 
with 1% uranyl acetate in 0.11 M veronal acetate buffer for 30 min. Cells were embedded 
in EmBed 812 (Electron Microscopy Sciences, Ft. Washington, PA). Ultrathin sections 
were poststained with uranyl acetate and lead citrate and viewed in a  Philips EM  300 
electron microscope. 
Results 
Production of Anti-HTLV p24 Monoclonal Antibodies.  After the fusion of mouse 
spleen cells with P3X63/Ag8,  NS1-Ag4,  or 653  rnyeloma cell lines, cells were 
plated into five 96-well microtiter plates per myeloma cell line. A  total of 542 
colony supernatants were screened in the solid-phase RIA for reactivity to HTLV 
proteins,  107 of which were positive. Four of the colony supernatants immuno- PALKER ET  AL.  1121 
precipitated a  24,000  dalton protein (p24) from  ~25I-labeled disrupted  HTLV, 
and these colonies were cloned, passaged as mouse ascites tumors, and designated 
as antibodies HTLV 6, 7, 8, and 9. Table I shows the fusion parents and isotypes 
of the anti-HTLV p24 monoclonal antibodies produced. 
Monoclonal antibodies HTLV  6,  7, 8, and 9  all reacted with a  24,000 dalton 
(p24) protein of HTLV  when tested in the Western blotting procedure against 
reduced and blotted HTLV proteins (Fig.  1). HTLV  6,  7, 8, and 9  also reacted 
with a  24,000 dalton protein of HTLV  under nonreducing conditions (data not 
shown). A control lane that contained blotted HTLV proteins was negative when 
similarly incubated with P3X63 ascites (Fig.  1D). 
To  further  characterize  monoclonal  antibodies  HTLV  6,  7,  8,  and  9,  the 
following criteria were established  for reactivity with  HTLV  gag-encoded p24 
internal core proteins: (a) Monoclonal anti-p24 antibodies should immunoprecip- 
itate the same p24  HTLV  protein that both HTLV + ATL patient (SD) serum 
and known polyclonal goat anti-HTLV p24 precipitate; and (b) monoclonal anti- 
p24  antibodies  should  react  with  HTLV-infected but  not  noninfected T  cells 
grown  in  culture.  Thus,  preclearing studies  were  undertaken  to  compare  the 
reactivities of HTLV  6,  7,  8,  and  9  with  those  of HTLV + ATL  patient  (SD) 
serum and goat antiserum  raised against  HTLV  p24.  To preclear HTLV  p24 
TABLE  I 
Anti-HTL  V P24 Monoclonal Antibodies 
HTLV 6  HTLV 7  HTLV 8  HTLV 9 
Clone  6G9  15C8  11 G6  6F 10 
Fusion parent  NS-1  P3X63/Ag8  P3X63/Ag8  NS-1 
Immunoglobulin isotype  IgG1  IgGl  IgG~  IgGl 
FIGURE  l.  Reactivity  of monoclonal antibodies HTLV 6, 7, 8, and 9 with p24 of HTLV. 
SDS-PAGE of disrupted  HTLV under reducing conditions and electrophoretic transfer to 
nitrocellulose were performed as described in Materials and Methods. After electrophoretic 
transfer of HTLV proteins, nitrocellulose strips were blocked with 3% BSA and incubated 
with hybridoma supernatants containing monoclonal antibody HTLV 6 (A), HTLV 7 (B), 
HTLV 9 (C), or supernatant  from mouse myeloma cell line P3X63 as negative control (/9). 
Binding of monoclonal antibodies to blotted  HTLV proteins was evaluated by incubating 
nitrocellulose strips with ~I-labeled F(ab')i fragment of sheep anti-mouse IgG + M, followed 
by washing and autoradiography for 2 h. HTLV 6, 7, and 9 recognized a 24,000 D protein 
of HTLV. HTLV 8 (not shown) also reacted with a p24 protein of HTLV in the Western 
blotting technique. '4C molecular weight markers were transferred  to the nitrocellulose and 
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FIGURE 2.  Precipitation of ~5I-labeled HTLV p24  by monoclonal antibody  HTLV 6.  To 
determine the amount of HTLV 6 antibody needed to precipitate the maximum number of 
counts  from  t~SI-labeled  HTLV  proteins,  varying  amounts  of  HTLV  6  were  incubated 
overnight with 5 x  105 cpm of t~SI-labeled HTLV proteins, immune complexes were precipi- 
tated  with  fixed Staphylococcus  aureus,  and  pellets  were  washed  and  counted  on  a  gamma 
counter. The titration curve shows that  10 #1 of HTLV 6  (0) was needed to precipitate the 
maximum amount of radiolabeled HTLV proteins.  Ascites fluid from mouse myeloma cell 
line P3X63 (O) was used as a negative control. 
FIGURE 3.  Monoclonal antibody HTLV 6 and antibodies in HTLV-associated ATL patient 
serum reacted with the same p24 protein of HTLV. Preclearing experiments were performed 
5  125  as described in Materials and Methods. Samples containing 5 x  10  cpm of  I-labeled HTLV 
proteins were first precleared with HTLV ATL patient SD serum and then radioimmunopre- 
cipitated (RIP) with HTLV 6 (le~) or precleared first with HTLV 6 and then precipitated with 
patient serum (right).  Preclearing with patient serum removed the p24 protein recognized by 
HTLV 6 (left, B), while preclearing with normal human serum (NHS) did not affect precipi- 
tation of p24 by HTLV 6 (F). (Left) Other controls were: (A) preclearing with patient serum, 
RIP with same; (C) preclearing with patient serum, RIP with NHS; (D) preclearing with patient 
serum, RIP with P3X63 ascites fluid; (E) preclearing with NHS, RIP with patient serum; (G) 
preclearing with NHS, RIP with NHS; (/4) preclearing with NHS,  RIP with P3X63  ascites 
fluid. (Right) Preclearing with HTLV 6 removed the HTLV p24 recognized by patient serum 
(C) while preclearing with P3X63 ascites fluid did not affect precipitation of p24  by HTLV 
ATL patient serum (G). Other controls are: (A) preclearing with HTLV 6, RIP with same; (B) 
preclearing with HTLV 6, RIP with P3X63; (D) preclearing with P3X63, RIP with NHS; (F) 
preclearing with P3X63 and RIP with same; (H) preclearing with NHS and RIP with same. 
protein  optimally from  l~I-labeled  disrupted  HTLV  with all  polyclonal goat, 
patient,  or  murine  monoclonal antibodies  assayed,  titration  curves  were  first 
derived by precipitating radiolabeled  HTLV proteins with varying amounts of 
antibody plus SAC.  Fig.  2  shows a  representative  precipitation  curve derived 
with monoclonal antibody HTLV-6. The amount of HTLV 6 ascites (10 ~1) that 
precipitated the maximum amount of l~SI-labeled p24  was  used in subsequent PALKER  ET  AL.  1123 
preclearing studies. Similar titration curves were generated using SD serum, goat 
anti-p24, and HTLV  7, 8, and 9. 
To determine whether SD serum and HTLV  6  precipitated the same 24,000 
dalton  protein,  l~sI-iabeled HTLV  samples (5  x  105  cpm/sample) were exten- 
sively precleared  by precipitation  with  SD  serum  and  SAC.  Precleared  HTLV 
samples were then precipitated with HTLV  6 plus SAC, and immunoprecipitates 
were compared with those obtained with control antibodies on a  10% polyacryl- 
amide gel  (Fig.  3,  left).  Preclearing of HTLV  samples with  SD serum removed 
most of the  pl9  and  p24  proteins  (lane A) and  also removed the  p24  protein 
recognized  by  HTLV  6  (lane  B).  In  contrast,  after  HTLV  samples  were  pre- 
cleared with normal human serum, SD serum precipitated HTLV  p19 and p24 
and  other  proteins  (lane E),  while  HTLV  6  precipitated  p24  (lane F).  Control 
precipitation experiments are shown in lanes C, D, G, and H  (see figure legend). 
When  ~2~I-HTLV samples were first precleared with HTLV  6  and then immu- 
FIGURE 4.  Monoclonal antibodies HTLV 6 and 7 each reacted with the same p24 of HTLV. 
Preclearing.. experiments, were, performed as described  in Materials and Methods. Samples 
containing 5 x  10  ~ cpm of  ~5I-labeled  HTLV proteins were first precleared  with HTLV 6 
and then radioimmunoprecipitated  with HTLV 7. Preclearing  with HTLV 6 removed the 
p24 protein of HTLV recognized  by HTLV 7 (C), while preclearing  with P3X63  did not 
inhibit precipitation  of p24 by HTLV 7 (F). Other controls are: (A) preclearing with HTLV 
6,  RIP with same; (B) preclearing  with  HTLV 6,  RIP with P3X63;  (D) preclearing  with 
P3X63, RIP with HTLV 6; (E) preclear with P3X63, RIP with same. HTLV 6 also precleared 
the p24  protein  precipitated  by monoclonal  antibodies  HTLV-8 and  HTLV 9  (data  not 
shown). 
FIGURE ,5.  Goat antiserum to purified HTLV p24 and HTLV 6 reacted with the same p24 
protein  of HTLV. Preclearing  experiments  were performed as described  in Materials and 
5  195  Methods. Samples containing  5 ×  10  cpm of  I-labeled HTLV proteins  were precleared 
first with goat antiserum  to purified  p24 (goat anti-p24) and then precipitated  (RIP) with 
HTLV 6. Preclearing with goat anti-p24 removed the p24 band recognized by HTLV 6 (C) 
while preclearing with normal goat serum (NGS) did not inhibit precipitation of p24 by HTLV 
6 (G). Other controls are: (A) preclearing with goat anti-p24, RIP with same; (B) preclearing 
with goat anti-p24,  RIP with NGS; (D) preclearing with goat anti-p24, RIP with P3X63; (E) 
preclearing with NGS, RIP with goat anti-p24; (F) preclearing with NGS, RIP with same; (/4) 
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noprecipitated with SD serum (Fig. 3, right), the p24 band was selectively removed 
(lane C) from those proteins immunoprecipitated by SD serum (lane G), confirm- 
ing that antibody HTLV 6  precipitated the HTLV p24 recognized by patient 
serum antibodies. Additional controls are shown in lanes A, B, D, F, and H  (see 
figure legend). 
The reactivity of HTLV 6 was then compared with reactivities of HTLV 7 in 
preclearing  experiments  shown  in  Fig.  4.  Preclearing  of radiolabeled  HTLV 
proteins with HTLV 6  removed the p24 protein recognized by HTLV 7 (Fig. 
4 C), while preclearing with control P3X63/Ag8 ascites did not remove the p24 
protein recognized by HTLV 7 (Fig. 4F). In similar experiments, HTLV 6 also 
precleared the p24 protein recognized by HTLV 8 and HTLV 9, indicating that 
monoclonal antibodies HTLV 6, 7, 8, and 9 all react with the same p24 protein. 
To further demonstrate that HTLV 6 reacts with the p24 internal core protein 
of HTLV, preclearing experiments were undertaken using goat antiserum raised 
to purified HTLV p24. As shown in Fig. 5, the goat antiserum to p24 precleared 
the p24 protein recognized by HTLV 6 (Fig. 5 C), whereas preclearing with the 
normal goat serum did not affect the subsequent precipitation of p24 by HTLV 
6 (Fig. 5 G). In contrast, preclearing with monoclonal antibody 12/1-2 directed 
against the p19 protein of HTLV did not affect the sequential precipitation of 
p24 by HTLV 6, and preclearing with HTLV 6 did not inhibit precipitation of 
the p19 protein by monoclonal antibody 12/1-2  (data not shown). 
To summarize the results of the preclearing experiments, monoclonal antibod- 
ies HTLV  6,  7,  8,  and  9,  goat anti-p24  antiserum and  HTLV  + ATL patient 
serum all reacted with the same p24 protein of HTLV. 
Antigenic Sites on HTLV p24 Recognized  by HTLV 6,  7, 8,  and 9 and by HTLV + 
Patient Sera.  To determine whether or not HTLV 6, 7, 8, and 9 recognize the 
same antigenic site or proximal sites on the p24 molecule, HTLV 6, 7, 8, and 9 
were purified over protein A-Sepharose 4B columns, radiolabeled, and allowed 
to compete with unlabeled HTLV 6, 7, 8, and 9 for binding to HTLV p24 in a 
competitive inhibition plate assay (Fig. 6A-D).  As controls, competition experi- 
ments performed with dilutions of unlabeled P3X63 ascites fluid and ~25I-labeled 
HTLV 6,  7,  8, and 9  were used to estimate  100%  binding in the plate assay. 
First, monoclonai antibodies HTLV  6 and 7, and to a  lesser extent HTLV  8, 
inhibited the binding of z~SI-labeled  HTLV 6 to HTLV p24 in a dose-dependent 
manner, while HTLV 9  did not inhibit binding (Fig.  6A).  We concluded that 
HTLV 6, 7, and possibly HTLV 8 recognized either the same or closely proximal 
antigenic sites on HTLV p24.  Next, in the same assay, unlabeled HTLV 6,  7, 
and  8  each  inhibited the binding of 125I-HTLV  7  (Fig.  6B) and  125I-HTLV 8 
(Fig.  6C)  to  HTLV  p24,  thus confirming that  HTLV  6,  7,  and  8  recognize 
either the same or closely proximal antigenic sites on p24. Neither HTLV 6 nor 
7  inhibited  the  binding of ~2~I-HTLV  9  to p24,  although HTLV  8  partially 
inhibited  12~I-HTLV 9  binding (Fig.  6D).  However, since unlabeled HTLV 9 
did not inhibit the binding of ~25I-HTLV 6, 7, or 8 to HTLV p24 (Fig. 6A-C), 
we concluded that  HTLV  9  recognizes a  different  site  than  the  site  or  sites 
recognized by HTLV 6,  7, and 8.  Thus, at least two antigenic sites on HTLV 
p24 were identified by HTLV 6, 7, 8, and 9: site A, which appears to react only PALKER  ET  AL.  1125 
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FIGURE 6.  Monoclonal antibodies HTLV 6, 7, 8, and 9 defined at least two distinct antigenic 
sites on HTLV p24. Competitive inhibition studies were performed as described in Materials 
and Methods. Briefly, duplicate microtiter wells precoated with HTLV proteins were incubated 
with dilutions of unlabeled HTLV 6,  7, 8, and 9, washed, and then further incubated with 
105 cpm of iodinated HTLV 6, 7, 8, and 9.  Wells were washed and the percent binding of 
radiolabeled antibody was evaluated. Control wells preincubated with dilutions of P3X63 or 
unlabeled HTLV 6, 7, 8, and 9 at 1:100 dilution were used as controls to estimate 100 and 
0% binding, respectively (HTLV 6 [O], HTLV 7 [×], HTLV 8 [A], HTLV 9 [ll]). (A) Binding 
of ~2~I-HTLV 6 to HTLV p24 is inhibited by unlabeled HTLV 6 and 7 and by HTLV 8 at 
low dilutions, but not by HTLV 9. (B) Binding of ]251-HTLV 7 to HTLV p24 is inhibited by 
~2s  unlabeled HTLV 6,  7, and 8, but not by HTLV 9.  (C) Binding of  I-HTLV 8 to p24 is 
inhibited by unlabeled HTLV 6, 7, and 8 but not by HTLV 9. (D) Binding of  I-HTLV 9 
to HTLV p24 is inhibited by unlabeled HTLV 9 and by HTLV 8 at low dilutions, but not by 
HTLV 6 or 7. Since unlabeled HTLV 9 does not block the binding of ~251-HTLV 6, 7, or 8 
to HTLV p24, it appears that HTLV 9 recognizes an antigenic site different from the site or 
sites recognized by HTLV 6, 7, and 8. Also, HTLV 6, 7, and 8 each inhibit the binding of 
x25I-HTLV 6, 7, and 8 to p24 and thus appear to recognize either the same antigenic site or 
proximal antigenic sites on the p24 molecule. 
with antibody HTLV  9, and an additional antigenic site (site[s] B) identified by 
antibodies HTLV  6,  7, and  8. 
To  determine  whether  or  not  HTLV ÷  patient  sera  or  other  human  sera 
positive  for  anti-HTLV  antibodies  recognize  the  same  sites  on  HTLV  p24 
identified by monoclonal antibodies HTLV  6, 7, 8, and 9, human  sera were used 
to inhibit the binding of 125I-HTLV 6, 7, 8, and 9  to HTLV  p24 in a  competitive 
binding assay. As shown in Table  II, HTLV ÷ ATL  or HTLV ÷ cutaneous T  cell 
lymphoma  patient serum partially inhibited the binding of ~25I-labeled HTLV  6, 
7, 8, and 9  to HTLV  p24.  In addition, two sera obtained from clinically normal 
HTLV-infected  family  members  of  HTLV ÷  patients  contained  antibodies  to 
HTLV  p24  that also inhibited the binding of ]~I-HTLV  6,  7,  8, and 9  to p24. 1126  MONOCLONAL  ANTIBODIES  TO  HTLV  p24  CORE  PROTEIN 
TABLE  II 
Inhibition of Binding of 12~Llabeled HTLV 6,  7, 8, and 9 to HTLV P24 by HTLV + 
Human Sera 
HTLV  ÷ human sera 
Percent inhibition of l~5I-labeled monoclonal antibody 
binding to HTLV p24" 
HTLV 6  HTLV 7  HTLV 8  HTLV 9 
SD*  27  23  ND  30 
WA  °  40  27  28  27 
No. 11  60  44  34  28 
No. 21  69  57  56  47 
Pooled normal serum  0  0  0  0 
* 100% inhibition obtained with 1:100 dilutions of unlabeled HTLV 6, 7, 8, or 9 and 
0%  inhibition obtained with pooled normal human serum from four subjects. All 
HTLV- control and HTLV  ÷ human sera were used at 1:2 dilution. ND, not done. 
s HTLV  ÷  Japanese ATL patient serum. 
0 HTLV  ÷ American cutaneous T  cell lymphoma patient serum. 
! Sera from clinically normal HTLV-infected family members of HTLV  ÷ patients. 
TABLE  III 
Reactivity  of Anti-p24 Monoclonal Antibodies with Human Cells* 
Cell line or source  s 
Percent positive 
HTLV 6  HTLV 7  HTLV 8  HTLV 9 
HUT 102 HTLV  ÷ T  cell  85  80  80  90 
SDJapanese ATL PBL after culture  j  100  100  100  100 
C3-44/MO HTLVn  ÷ cells  !  21  98  100  99 
Fresh normal PBL  0  0  0  0 
Fresh normal PBL after 4 d in culture  j  0  0  0  0 
Normal PBL after Con A (50 ttg/ml) activation  ~  0  0  0  0 
HSB-2 HTLV- T  cell  0  0  0  0 
EB-3 B cell  0  0  0  0 
HUT 78 HTLV- T  cell**  0  0  0  0 
* Reactivity of monoclonal antibodies determined by indirect immunofluorescence  on acetone-fixed 
cytocentrifuge preparations of cells. 
g  Japanese ATL cells cultured 5 d  in 25% crude T  cell growth factor. Fresh PBL cultured 4 d in 
media. 
Normal PBL cultured 4 d in Con A (50 #g/ml). 
** HUT 78 cells are p19 (15) and p24 (11) negative. 
Other tissues tested in indirect immunofluorescence  assays with HTLV 6, 7, 8, and 9 and found 
to be negative: thymus, lymph node, tonsil, spleen, kidney, liver, pancreas, adrenal, brain cortex 
and medulla oblongata, adenocarcinoma of lung and prostate, melanoma, breast carcinoma (3), 
and infiltrating T  cells in skin from HTLV  ÷ ATL patient SD. 
! C3-44/MO is a T  cell cord blood line infected with HTLVIIMo, a new type of HTLV (25). 
In contrast, pooled normal human serum did not inhibit binding of ~25I-HTLV 
6, 7, 8, and 9 to p24. Thus, anti-p24 antibodies in HTLV  + human sera reacted 
with antigenic sites on p24 that are also recognized by HTLV 6, 7, 8, and 9. 
Tissue and Cellular Specificity of Anti-HTLV p24 Monoclonal Antibodies.  Table III 
demonstrates that  all four anti-p24  monoclonal  reagents reacted only with the 
HTLV  + malignant  T  cells tested and did not react with HTLV- T  cells, fresh 
normal  PBL,  B  cell  lines,  mitogen-activated  normal  T  cells,  or any of a  large 
panel of normal human tissues. Also, HTLV 6, 7, 8, and 9 reacted with acetone- PALKER  ET  AL.  1127 
fixed cord blood  T  cells (C3-44/Mo)  that  were infected with HTLVn,  a  new 
type of HTLV (25). Thus, the antigenic sites of HTLV p24 identified by these 
antibodies are conserved in a cell line infected by HTLVn. 
When treated with HTLV 6,  7,  8, and 9 in an indirect immunofluorescence 
assay,  acetone-fixed HUT-102  HTLV-infected T  cells demonstrated positive 
fluorescence localized in discrete patches at or near the cell surface or at  the 
interface of cell  to  cell contact (arrows,  Fig.  7).  Also,  5%  of HUT  102  cells 
appeared to contain intracytoplasmic fluorescence (arrowhead, Fig.  7).  Type C 
virus particles were frequently seen between adjacent HUT 102 cells by electron 
microscopy (I 0) (arrows, Fig.  8) and probably account for the intense anti-p24 
fluorescent staining localized between adjacent HUT-102 cells (Fig.  7).  In con- 
trast,  none  of the  anti-p24  monoclonal  antibodies  reacted  with  cell  surface 
antigens on viable non-acetone-fixed HUT-102 cells in suspension, as shown by 
the fluorescence-activated cell sorter histogram in Fig.  9.  These data are com- 
patible with the notion that p24 is an internal viral core protein and suggest that 
p24 is sequestered in budding virus particles at or near the surface of most HUT- 
102 cells. 
Discussion 
In this study we report the production and diagnostic use of four monoclonal 
antibodies to disrupted HTLV, HTLV 6, 7,  8, and 9, all of which reacted with 
the p24 internal core protein of HTLV. All four monoclonal antibodies reacted 
with the same p24 HTLV protein.  Moreover, these antibodies all reacted with 
the same p24 HTLV protein recognized by antibodies in HTLV  + ATL patient 
(SD) serum and by polyclonal goat antisera to purified HTLV p24 internal core 
FIGURE 7.  Immune fluorescence of HTLV  ÷ acetone-fixed HUT-102 cells using monoclonal 
antibody HTLV  6.  HTLV  p24  was  localized in discrete polar patches at  or near the cell 
surface and between adjacent cells (arrows).  Also, 5% of cells had intracytoplasmic anti-p24 
fluorescence (arrowheads). Similar fluorescent staining of HUT  102 cells was also seen with 
HTLV 7, 8, and 9 (not shown). X 400. 1 128  MONOCLONAL  ANTIBODIES  TO  HTLV p24  CORE PROTEIN 
FIGURE 8.  Electron micrographs of HTLV from HUT-102 cells. Electron micrograph of 
adjacent HUT 102 cells showing extracellular HTLV particles (arrows) between cells. Inserts: 
High magnification of extracellular particles (arrows) between adjacent HUT-102 cells. 
i  dlqrl-t~4  AIVrI-ICLA  A,B,C 
LINEAR FLUORESCENCE INTEN$1TY 
FIGURE  9.  Fluorescence-activated  cell sorter histogram of nonreactivity of monoclonal anti- 
body HTLV 6 on viable HTLV  ÷ HUT 102 cells, showing negative cell surface fluorescence. 
HUT 102 T cells were positive when stained for the presence of nonpolymorphic HLA with 
monoclonal antibody 3F 10.  P3X63  ascites fluid (- -  -) was used as a negative control. 
protein.  Screening of HTLV  6,  7,  8,  and  9  against  a  comprehensive panel  of 
normal, neoplastic, and virus-infected human tissues and cells indicated that these 
monoclonal antibodies selectively identify only those cells that are infected with 
HTLV  and  express  mature  virions.  A  previous  study  (15)  with  monoclonal 
antibody 12/1-2  directed against the p l 9  protein of HTLV demonstrated that 
antibody  12/1-2  react with an  antigenic  determinant on normal  non-HTLV- 
infected human endocrine thymic epithelium and on the basal  layer of keratin- 
ocytes in  squamous  epithelium  (15).  In  contrast,  the  reactivity of monoclonal PALKER  ET  AL.  1129 
anti-HPLV p24 antibodies HTLV 6, 7, 8, and 9 is restricted to T  cells infected 
with HTLV. 
In competitive inhibition  studies,  HTLV  6,  7,  and  8  recognized either the 
same antigenic site or proximal antigenic sites on HTLV p24,  while HTLV 9 
reacted with a unique site distinct from the site or sites recognized by HTLV 6, 
7, and 8. Also, HTLV 6,  7, 8, and 9 reacted with fixed cord blood T  (C3-44/ 
Mo) cells that were infected with HTLVm a human type C retrovirus reported 
to be a new type of HTLV (25). Thus, the HTLV p24 antigenic sites identified 
by these antibodies are conserved in a cell line infected by HTLVII and are likely 
to be associated with the p24 of HTLVH. In addition, the antigenic determinants 
of p24 detected by our monoclonal antibodies are immunogenic in man, since 
HTLV  ÷ patient sera blocked the binding of ~25I-labeled HTLV 6, 7, 8, and 9 to 
HTLV p24 in a competitive RIA. 
Using anti-HTLV p24 antibodies, we have shown that HTLV p24 is localized 
at or near the cell surface of 95% of acetone-fixed HTLV  ÷ HUT 102 cells. The 
p24  antigen was not detectable on the cell surface of viable HTLV ÷ cells, as 
demonstrated by data obtained with indirect fluorescence techniques and cell 
sorter analysis (Fig. 9). Polar areas of HTLV ÷ T  cells and areas between adjacent 
HUT 102 cells were strongly p24 positive by indirect immunofluorescence (Fig. 
7);  these  are  areas  where  HTLV  virions  frequently are  demonstrated  with 
electron microscopy (10) (Fig. 8). These data suggest that HTLV p24 is seques- 
tered in the virus particles budding from the surface of the HTLV-infected cells. 
In addition,  monoclonal antibodies  HTLV  6,  7,  8,  and  9  and  12/1-2  (anti- 
HTLV  p19)  infrequently  (5)  react  with  diffuse  cytoplasmic  components  of 
HTLV  ÷ T  cells. This may indicate that the precursor molecule encoded by the 
gag region of HTLV  undergoes posttranslational  modification at or near the 
cell membrane, thereby giving rise to the pl 9 and p24 epitopes defined by these 
monoclonal  antibodies  (26).  Finally,  the  use  of directly fluoresceinated anti- 
HTLV p24 monoclonal antibodies in a one-step fluorescent assay on 5-d cultured 
PBL appears to be a simple and highly specific test for HTLV-infected cells. 
It is hoped that these monoclonal antibodies will be useful diagnostic probes 
to  detect  HTLV-infected cells  and  to  discriminate  between  the  subtypes  of 
HTLV associated with adult T  cell leukemia, the T  cell variant of hairy cell 
leukemia, and other diseases potentially associated with HTLV or variants of 
HTLV, such as the acquired immunodeficiency syndrome. 
Summary 
Four monoclonal antibodies, human T  cell leukemia-lymphoma virus (HTLV) 
6,  7,  8,  and  9,  which react  with  the  24,000  dalton  internal  core protein  of 
HTLV~, have been developed. These monoclonal antibodies reacted with only 
HTLV-infected cells  and  not  with  a  broad  spectrum  of normal,  neoplastic, 
mitogen-stimulated, or virus-infected cells and  tissues.  HTLV  6,  7,  8,  and  9 
identified at least two different antigenic determinants on HTLV p24 that were 
also  recognized  by  antibodies  present  in  HTLV ÷  patient  sera.  Monoclonal 
antibodies HTLV 6, 7, 8, and 9 reacted in indirect immunofluorescence assays 
with HTLV p24 localized at the cell surface of 5-d cultures of HTLV-infected 
T  cells and, as well, reacted with T  cells infected with HTLVm a  new type of 1130  MONOCLONAL ANTIBODIES TO  HTLV p24  CORE  PROTEIN 
HTLV  isolated from a  patient (MO) with a  T  cell variant of hairy cell leukemia. 
Thus, HTLV  6, 7, 8, and 9  should prove to be useful diagnostic reagents in the 
identification of HTLV- and HTLVn-infected T  cells. 
Received for publication I December 1983. 
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